Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma

Qiuju PENG; Tao DAI; Guibo XIE; Jinjun CHEN; Xiao CHENG; Yuan YAN

doi:10.3969/j.issn.1001-5256.2023.07.033

Volume 39 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(7): 1740-1746

PDF( 1735 KB)

Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.07.033

a.
Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
b.
Department of Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Research funding:

National Natural Science Foundation of China (82070650);

National Science and Technology Major Project (2018ZX10723203);

National Science and Technology Major Project (2018ZX10302206)

More Information

Corresponding author: YAN Yuan, 616756657@qq.com (ORCID: 0000-0002-1044-2457)
Received Date: 2022-10-31
Accepted Date: 2022-12-18
Published Date: 2023-07-20

Abstract

Abstract

Transcatheter arterial chemoembolization (TACE) is recommended by domestic and international guidelines for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), and it is one of the most common treatment methods for patients with uHCC. The chemotherapy drugs commonly used in TACE for HCC include epirubicin, cisplatin, and fluorouracil, while it is still unclear which chemotherapy drug has a better clinical effect. This article summarizes the studies of different TACE regimens using different chemotherapy drugs in the treatment of patients with uHCC in the recent five years. TACE combined with sorafenib can significantly improve the survival of patients with advanced HCC and has been recommended for the treatment of such patients by Chinese Society of Clinical Oncology guidelines, and the efficacy of TACE combined with other tyrosine kinase inhibitors (TKI) has become a research hotspot. Studies have shown that compared with TACE combined with sorafenib in the treatment of patients with advanced HCC, TACE combined with lenvatinib can achieve a significantly longer progression-free survival time and a tendency of increase in median overall survival time. However, due to the variation of target receptors or downstream signals, resistance to molecular-targeted agents is still a challenging problem. TKI combined with immune checkpoint inhibitors may be a promising strategy for the treatment of patients with uHCC. Some studies suggest that triple therapy using TACE combined with TKIs and anti-PD-1/PD-L1 monoclonal antibody has better efficacy in improving the survival of patients with uHCC. This article reviews the studies of the efficacy and safety of TACE combined with targeted agents and TACE combined with anti-PD-1/PD-L1 monoclonal antibody in the treatment of patients with uHCC in the recent five years.
- Carcinoma, Hepatocellular,
- Chemoembolization, Therapeutic,
- Molecular Targeted Therapy,
- Immune Checkpoint Inhibitors,
- Drug Therapy, Combination

FullText(HTML)

References(36)

References

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[3]	Chinese Society of Clinical Oncology. Guidelines for diagnosis and treatment of primary liver cancer (2022 edition)[M]. Beijing: People's Medical Publishing House, 2022. 中国临床肿瘤学会. 原发性肝癌诊疗指南(2022年版)[M]. 北京: 人民卫生出版社, 2022.
[4]	NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^Ⓡ)[EB/OL]. Hepatobiliary Cancers. Version 1.2022. https://www.nccn.org/.
[5]	RAOUL JL, FORNER A, BOLONDI L, et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence[J]. Cancer Treat Rev, 2019, 72: 28-36. DOI: 10.1016/j.ctrv.2018.11.002.
[6]	LO CM, NGAN H, TSO WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5): 1164-1171. DOI: 10.1053/jhep.2002.33156.
[7]	LLOVET JM, REAL MI, MONTAÑA X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739. DOI: 10.1016/S0140-6736(02)08649-X.
[8]	ARAMAKI O, TAKAYAMA T, MORIGUCHI M, et al. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial[J]. Eur J Cancer, 2021, 157: 373-382. DOI: 10.1016/j.ejca.2021.08.027.
[9]	IKEDA M, KUDO M, AIKATA H, et al. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase Ⅲ randomized trial[J]. J Gastroenterol, 2018, 53(2): 281-290. DOI: 10.1007/s00535-017-1374-6.
[10]	Chinese College of Interventionalists, Chinese Medical Doctor Association. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma[J]. Chin J Intern Med, 2021, 60(7): 599-614. DOI: 10.3760/cma.j.cn112137-20210425-00991. 中国医师协会介入医师分会临床诊疗指南专委会. 中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2021年版)[J]. 中华内科杂志, 2021, 60(7): 599-614. DOI: 10.3760/cma.j.cn112137-20210425-00991.
[11]	FU J, WANG Y, ZHANG J, et al. The safety and efficacy of transarterial chemoembolisation with bleomycin for hepatocellular carcinoma unresponsive to doxorubicin: a prospective single-centre study[J]. Clin Radiol, 2021, 76(11): 864. e7-864. e12. DOI: 10.1016/j.crad.2021.07.013.
[12]	WANG Y, FU JX, ZHANG JL, et al. Transarterial chemoembolization with bleomycin treatment for moderate-advenced hepatocellular carcinoma[J]. Nat Med J China, 2018, 98(39): 3166-3170. DOI: 10.3760/cma.j.issn.0376-2491.2018.39.008. 王燕, 付金鑫, 张金龙, 等. 博来霉素经肝动脉化疗栓塞治疗中晚期肝癌的临床观察[J]. 中华医学杂志, 2018, 98(39): 3166-3170. DOI: 10.3760/cma.j.issn.0376-2491.2018.39.008.
[13]	BESSAR AA, FARAG A, ABDEL MONEM SM, et al. Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study[J]. Eur Radiol Exp, 2021, 5(1): 10. DOI: 10.1186/s41747-021-00204-6.
[14]	ZHANG Z, WU Y, ZHENG T, et al. Efficacy of transarterial chemoembolization combined with molecular targeted agents for unresectable hepatocellular carcinoma: A network meta-analysis[J]. Cancers (Basel), 2022, 14(15). DOI: 10.3390/cancers14153710.
[15]	SCHICHO A, HELLERBRAND C, KRÜGER K, et al. Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels[J]. J Clin Transl Hepatol, 2016, 4(4): 288-292. DOI: 10.14218/JCTH.2016.00058.
[16]	SERGIO A, CRISTOFORI C, CARDIN R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness[J]. Am J Gastroenterol, 2008, 103(4): 914-921. DOI: 10.1111/j.1572-0241.2007.01712.x.
[17]	KUDO M, UESHIMA K, IKEDA M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69(8): 1492-1501. DOI: 10.1136/gutjnl-2019-318934.
[18]	LEE TY, LIN CC, CHEN CY, et al. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial[J]. Medicine (Baltimore), 2017, 96(37): e7655. DOI: 10.1097/MD.0000000000007655.
[19]	XU X, MENG Q. Drug effect analysis of sorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma[J]. Pak J Pharm Sci, 2018, 31(4(Special)): 1751-1755.
[20]	CAI R, SONG R, PANG P, et al. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis[J]. BMC Cancer, 2017, 17(1): 714. DOI: 10.1186/s12885-017-3707-5.
[21]	DING X, SUN W, LI W, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study[J]. Cancer, 2021, 127(20): 3782-3793. DOI: 10.1002/cncr.33677.
[22]	LU W, JIN XL, YANG C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial[J]. Cancer Biol Ther, 2017, 18(6): 433-438. DOI: 10.1080/15384047.2017.1323589.
[23]	ZHAO S, ZHANG T, DOU W, et al. A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis[J]. Ann Transl Med, 2020, 8(8): 542. DOI: 10.21037/atm.2020.02.125.
[24]	CAO Y, SUN T, GUO X, et al. Sorafenib versus apatinib both combined transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: A comparative retrospective study[J]. Front Oncol, 2021, 11: 673378. DOI: 10.3389/fonc.2021.673378.
[25]	QIU Z, SHEN L, JIANG Y, et al. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study[J]. Ann Transl Med, 2021, 9(4): 283. DOI: 10.21037/atm-20-5360.
[26]	GUO W, CHEN S, WU Z, et al. Efficacy and safety of transarterial chemoembolization combined with anlotinib for unresectable hepatocellular carcinoma: A retrospective study[J]. Technol Cancer Res Treat, 2020, 19: 1533033820965587. DOI: 10.1177/1533033820965587.
[27]	TURPIN A, de BAERE T, HEURGUÉ A, et al. Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study[J]. Clin Res Hepatol Gastroenterol, 2021, 45(2): 101464. DOI: 10.1016/j.clinre.2020.05.012.
[28]	XU Q, HUANG Y, SHI H, et al. Sunitinib versus sorafenib plus transarterial chemoembolization for inoperable hepatocellular carcinoma patients[J]. J BUON, 2018, 23(1): 193-199.
[29]	CHAN SL, YEO W, MO F, et al. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma[J]. Cancer, 2017, 123(20): 3977-3985. DOI: 10.1002/cncr.30825.
[30]	ZHANG S, ZHAO Y, HE L, et al. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2022, 46(4): 101851. DOI: 10.1016/j.clinre.2021.101851.
[31]	YU SL, LIU DH, WANG C, et al. TACE combined with camrelizumab for treatment of advanced hepatocellular carcinoma[J]. Chin J Interv Imaging Ther, 2022, 19(7): 391-395. DOI: 10.13929/j.issn.1672-8475.2022.07.003. 于士龙, 刘东辉, 王储, 等. TACE联合卡瑞利珠单抗治疗中晚期肝细胞癌[J]. 中国介入影像与治疗学, 2022, 19(7): 391-395. DOI: 10.13929/j.issn.1672-8475.2022.07.003.
[32]	MOU L, TIAN X, ZHOU B, et al. Improving outcomes of tyrosine kinase inhibitors in hepatocellular carcinoma: New data and ongoing trials[J]. Front Oncol, 2021, 11: 752725. DOI: 10.3389/fonc.2021.752725.
[33]	ZHANG X, ZHU X, LIU C, et al. The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2022, 40(4_suppl): 453-453. DOI: 10.1200/JCO.2022.40.4_suppl.453
[34]	LI W, PEI Y, WANG Z, et al. Efficacy of transarterial chemoembolization monotherapy or combination conversion therapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis[J]. Front Oncol, 2022, 12: 930868. DOI: 10.3389/fonc.2022.930868.
[35]	LLOVET JM, VOGEL A, MADOFF DC, et al. Randomized phase 3 LEAP-012 study: Transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment[J]. Cardiovasc Intervent Radiol, 2022, 45(4): 405-412. DOI: 10.1007/s00270-021-03031-9.
[36]	WANG K, YU HM, XIANG YJ, et al. Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase Ⅱ trial[J]. Future Oncol, 2022, 18(30): 3367-3375. DOI: 10.2217/fon-2022-0188.

Relative Articles

[1]	Development Committee of Clinical Practice Guidelines for Robotic Hepatopancreatobiliary Surgery. Clinical practice guidelines for robotic hepatopancreatobiliary surgery[J]. Journal of Clinical Hepatology, 2019, 35(7): 1459-1471. doi: 10.3969/j.issn.1001-5256.2019.07.009
[2]	Development Committee of Clinical Practice Guidelines for Laparoscopic Hepatopancreatobiliary Surgery. Clinical practice guidelines for laparoscopic hepatopancreatobiliary surgery[J]. Journal of Clinical Hepatology, 2019, 35(7): 1450-1458. doi: 10.3969/j.issn.1001-5256.2019.07.008
[3]	Xu YanLing, Zhao Xu, Guo XiaoLin, Ji HuiFan, Zhang Ying, Song XinYue, Wang JingYu, Sun XiaoFeng, Liu Kai, He RongHua, Gao PuJun. Clonorchiasis complicated by multiple cholelithiasis and cholestatic cirrhosis misdiagnosed as Budd-Chiari syndrome: A case report[J]. Journal of Clinical Hepatology, 2018, 34(7): 1514-1516. doi: 10.3969/j.issn.1001-5256.2018.07.029
[4]	Zhao GuoPing, Hu JianPing, Wang JiRong. Clinical experience in choledochoscopy for the treatment of intrahepatic bile duct stones complicated by biliary stricture:a clinical analysis of 230 cases[J]. Journal of Clinical Hepatology, 2017, 33(11): 2166-2169. doi: 10.3969/j.issn.1001-5256.2017.11.023
[5]	Jiang Chao, Wang HaiJiu, Ren Li, Yang DanCaiRang, Hou LiChao, Zhou Ying, Wen Hao, Fan HaiNing. Application status of three- dimensional CT reconstruction in hepatobiliary surgery[J]. Journal of Clinical Hepatology, 2017, 33(2): 389-393. doi: 10.3969/j.issn.1001-5256.2017.02.041
[6]	Lu Xia, Jia HaiMing, Mi TaiYu, Zhang WenQuan, Gao Peng. Effect of fast track surgery on anxiety index and stress indices in patients undergoing laparoscopic cholecystectomy[J]. Journal of Clinical Hepatology, 2017, 33(2): 308-312. doi: 10.3969/j.issn.1001-5256.2017.02.022
[7]	Wu Xiao, Xia Hao, Wu Jian, Zhang Ming. Clinical experience in treatment of complex intrahepatic bile duct stones by regular hepatectomy[J]. Journal of Clinical Hepatology, 2016, 32(9): 1756-1759. doi: 10.3969/j.issn.1001-5256.2016.09.025
[8]	Wu ErBin, Zhang JinWei. Clinical application of selective intraoperative cholangiography in biliary system surgery[J]. Journal of Clinical Hepatology, 2016, 32(7): 1357-1359. doi: 10.3969/j.issn.1001-5256.2016.07.031
[9]	Chen ZhiYu, Bie Ping. Clinical application of combined vascular resection and reconstruction in surgical treatment of hilar cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2016, 32(7): 1277-1279. doi: 10.3969/j.issn.1001-5256.2016.07.011
[10]	Han Wei, Yue Qing, Yan JingZhe, Jia BaoXing, Wang YingChao, Liu YaHui. Concept of fast-track surgery and its application in perioperative period of hepatectomy for liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(10): 2007-2011. doi: 10.3969/j.issn.1001-5256.2016.10.044
[11]	Qi WenLei, Zhang RuoYan, Chai WenGang, Liu MingJiang, Du XiaoHong, Ye JunFeng. Diagnosis of clonorchiasis during and after biliary tract surgery: a clinical analysis of 15 cases[J]. Journal of Clinical Hepatology, 2016, 32(11): 2134-2137. doi: 10.3969/j.issn.1001-5256.2016.11.026
[12]	Cheng XiangChao, Yuan QiDong, Zhao JianHong, Liu Bin. Percutaneous transhepatic approach for intrahepatic and extrahepatic bile duct stones: a clinical analysis of 19 cases[J]. Journal of Clinical Hepatology, 2015, 31(10): 1685-1687. doi: 10.3969/j.issn.1001-5256.2015.10.031
[13]	Zhang HaoYu, Liu Bin. Research advances in surgical treatment of intrahepatic bile duct stones[J]. Journal of Clinical Hepatology, 2015, 31(10): 1726-1729. doi: 10.3969/j.issn.1001-5256.2015.10.046
[14]	Li QiNan, Zhang YuHuai, Geng Jie. Safety and efficacy of fast-track surgery in perioperative nursing for biliary calculi surgery: a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1660-1664. doi: 10.3969/j.issn.1001-5256.2015.10.025
[15]	Xing TongChao, Ren Bin, Wang YuPeng, Yang DongXing. Clinical effect of choledochofiberscope-assisted secondary surgery in treatment of intrahepatic and extrahepatic biliary stones[J]. Journal of Clinical Hepatology, 2015, 31(8): 1325-1327. doi: 10.3969/j.issn.1001-5256.2015.08.036
[16]	Li Jiang, Liu Bin. More attention to initial surgical treatment of hepatolithiasis[J]. Journal of Clinical Hepatology, 2015, 31(10): 1612-1614. doi: 10.3969/j.issn.1001-5256.2015.10.012
[17]	Tang CaiXi, Zhao ZhiJian, Feng Bin, Yang KaiQing. Surgical treatment of cholangiolithiasis with cavernous transformation of the portal vein: a review and analysis of 18 cases[J]. Journal of Clinical Hepatology, 2014, 30(1): 39-41. doi: 10.3969/j.issn.1001-5256.2014.01.013
[18]	Lu: WenPing. Clinical classification of hepatolithiasis and choice of surgical strategy[J]. Journal of Clinical Hepatology, 2013, 29(6): 404-406+410.
[19]	Wu LiMing, Cheng CaiTao, Wang JiangHua, Chen XianXiang. Clinical effect of laparoscopic reoperation combined with choledochoscope in treatment of intra-and extrahepatic bile duct stones:analysis of 35 cases[J]. Journal of Clinical Hepatology, 2013, 29(7): 516-519. doi: 1001-5256 (2013) 07-0516-04
[20]	Ou Xi, Xiong Pei, Ye JianYu, Liu JiKui. Application of medical obturation glue in the treatment of hepatolithiasis with laparoscopic hepatectomy[J]. Journal of Clinical Hepatology, 2011, 27(9): 927-930.

Supplements(0)

Cited By

Cited by

Periodical cited type(13)

1.	路燕，陈明月，郑秀良，雷宇. 185例药物性肝损伤患者的临床特征分析. 安徽医学. 2022(03): 308-313 .
2.	赵临潇，左博云，李静亚，于东升. 妊娠期肝内胆汁淤积症孕妇胎盘ABCB4基因表达与妊娠结局的关系. 海南医学. 2022(11): 1424-1427 .
3.	张慧芳，王高莹，邹萍，王晶，董蕊锐，张婷，孟西娜. 妊娠期肝内胆汁淤积症血清甘胆酸水平与妊娠结局的关系. 中国临床研究. 2022(06): 793-796 .
4.	林洪萍，黄晋萍，黄淑兰，卢君，黎春，杨佳柳. 中药外洗在妊娠期肝内胆汁淤积症诱发皮肤瘙痒患者中的应用. 中国医学创新. 2022(19): 96-99 .
5.	李媛，郑泽玉，田阗，邬洪明，田嫣然，李茂. 妊娠期肝内胆汁淤积症的危险因素分析. 临床和实验医学杂志. 2021(02): 200-203 .
6.	段兴平，王燕，黄常友，郑会贤，罗一，覃正文，任郁. 妊娠期肝病的临床特征及研究进展. 临床肝胆病杂志. 2020(06): 1407-1411 . 本站查看
7.	陈韵洁，张晨，谭娟. 脂肪酸转运体蛋白FATP4、CD36、FABP1在妊娠期肝内胆汁淤积胎盘中表达研究. 中外医疗. 2020(15): 30-31+46 .
8.	唐照青，俞海珍. 联合监护评估对妊娠期无症状高胆汁酸血症孕妇围生儿预后的价值. 中国现代药物应用. 2020(18): 19-22 .
9.	汪学耀，张涛，荆成宝. 血清总胆汁酸与甘胆酸水平诊断妊娠期肝内胆汁淤积症能力的Meta分析. 现代检验医学杂志. 2020(05): 73-76 .
10.	吕玉清. 我院中药处方中妊娠患者疾病及用药情况分析研究. 海峡药学. 2020(10): 176-178 .
11.	刘燕，王丽娟，李盈盈. 综合护理在妊娠期肝内胆汁淤积症患者中的临床效果分析. 妇产与遗传(电子版). 2020(03): 40-44 .
12.	张燕，王伟红. 妊娠期肝内胆汁淤积症孕妇血清总胆汁酸、谷草转氨酶及Th17/Treg平衡水平及临床意义. 中国计划生育学杂志. 2020(12): 2093-2097 .
13.	马艳辉，邵久玲，王双梅. 低分子肝素治疗妊娠期肝内胆汁淤积症的疗效及对肝胆指标、母婴结局的影响. 哈尔滨医药. 2020(05): 438-440 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (440) PDF downloads(49)

Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2023.07.033